Chondoadherin as a biomarker in patients with endometrial cancer

Early diagnosis and development of newer and more effective treatments for endometrial cancer, which is observed so frequently, continue to be necessary. In the present study, we aimed to show the relationship between the tumorigenesis of endometrial cancer and chondoadherin and its place as a biomarker. A total of 15 patients diagnosed with endometrioid adenocarcinoma in the pathology unit of the present tertiary hospital and 15 patients operated for non-tumor reasons between 2019 and 2020 were included in the study. Pathology tumor blocks were selected for ELISA and PCR study in which chondoadherin gene expression and protein levels were measured. We found increased expression of the chondoadherin-like (CHADL) gene in endometrial cancer cells compared to endometrial cells without tumor diagnosis (2.85 ± 0.44 vs. 1.94 ± 0.33). When the mean value for the protein level in CHADL tissues was examined, we found a higher rate in endometrial cancer tissues (228.83 ± 22.30 vs. 186.66 ± 21.09). The CHADL protein level and gene expression increased as the grade increased. The present study is the first report presenting chondoadherin level in endometrial cancer. Chondoadherin level in endometrial cancer can be a guiding marker in early diagnosis and treatment process and prognosis. KEY WORDS: Biomarker, Chondoadherin, Endometrial cancer.